JP2010022372A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010022372A5 JP2010022372A5 JP2009205660A JP2009205660A JP2010022372A5 JP 2010022372 A5 JP2010022372 A5 JP 2010022372A5 JP 2009205660 A JP2009205660 A JP 2009205660A JP 2009205660 A JP2009205660 A JP 2009205660A JP 2010022372 A5 JP2010022372 A5 JP 2010022372A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody molecule
- seq
- dna
- cdr
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (26)
- ヒトCD22に対する特異性を有する抗体分子であって、
重鎖として、可変ドメインが、CDR−H1について配列番号1に示す配列、CDR−H2について配列番号2に示す配列もしくは図6におけるgH1の配列GINPGNQYTTYKRNLKG、およびCDR−H3について配列番号3に示す配列を含むものを含み、
軽鎖として、可変ドメインが、CDR−L1について配列番号4に示す配列、CDR−L2について配列番号5に示す配列およびCDR−L3について配列番号6に示す配列を含むものを含み、キメラ抗体分子またはCDR移植分子である、抗体分子。 - 可変ドメインは、ヒトアクセプターフレームワーク領域を含む、請求項1の抗体分子。
- 重鎖の可変ドメインのヒトアクセプターフレームワーク領域が配列番号21および22に基づき、配列番号8の1、28、48、72および97位の残基にそれぞれ対応する、Kabatによる番号付けで1、28、48、71および93位のドナー残基の1つまたは2つ以上を含む、請求項2の抗体分子。
- 配列番号8の68および/または70位の残基にそれぞれ対応する、Kabatによる番号付けで67と69位のドナー残基をさらに含む、請求項3の抗体分子。
- 軽鎖の可変ドメインのヒトアクセプターフレームワーク領域が、配列番号17および18に基づき、配列番号7の2、4、42、43、50および65位の残基にそれぞれ対応する、Kabatによる番号付けで2、4、37、38、45および60位のドナー残基1つまたは2つ以上を含む、請求項2〜4のいずれか1項の抗体分子。
- 配列番号7の位置の残基に対応する、Kabatによる番号付けで3位のドナー残基をさらに含む、請求項5の抗体分子。
- 請求項3または請求項4の重鎖と、請求項5または請求項6の軽鎖とを含む、ヒトCD22に対する特異性を有する抗体分子。
- 軽鎖可変領域5/44−gL1(配列番号19)と重鎖可変領域5/44−gH1(配列番号23)とを含む、請求項1の抗体分子。
- それぞれ配列番号7と配列番号8に記載の軽鎖および重鎖可変ドメインの配列を含むキメラ抗体分子である、請求項1の抗体分子。
- 請求項1〜9のいずれか1項の抗体分子の重鎖および/または軽鎖をコードするDNA。
- 請求項10のDNAを含むクローニングベクターまたは発現ベクター。
- 請求項11のクローニングベクターまたは発現ベクターを含む宿主細胞。
- 治療で使用される、請求項1〜9のいずれか1項の抗体分子。
- 悪性リンパ腫を治療するのに使用される、請求項1〜9のいずれかの抗体分子。
- 悪性リンパ腫は非ホジキンリンパ腫である、請求項14の抗体分子。
- CD22を発現する細胞により仲介される病態の治療のための、ヒトCD22に対する特異性を有する請求項1〜9のいずれか1項の抗体分子、または請求項10のDNAを含む医薬組成物。
- 病態が悪性リンパ腫である、請求項16の医薬組成物。
- 病態が非ホジキンリンパ腫である、請求項17の医薬組成物。
- 請求項1〜9のいずれか1項の抗体分子または請求項10のDNAを含む診断用組成物。
- 薬剤学的に許容される賦形剤、希釈剤または担体を含む、請求項17または18の医薬組成物。
- 抗T細胞、抗IFNγ、または抗LPS抗体、またはキサンチンのような非抗体成分をさらに含む、請求項17または請求項18の医薬組成物。
- 請求項1〜9のいずれか1項の抗体分子の製造方法であって、該抗体分子をコードするDNAからのタンパク質の発現に適した条件下で請求項12の宿主細胞を培養し、該抗体分子を単離することを特徴とする、上記方法。
- 治療で使用される、請求項10のDNA。
- CD22を発現する細胞により仲介される病態の治療のための、請求項10のDNA。
- 悪性リンパ腫を治療するのに使用される、請求項10のDNA。
- 悪性リンパ腫は非ホジキンリンパ腫である、請求項25のDNA。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0210121.0 | 2002-05-02 | ||
GBGB0210121.0A GB0210121D0 (en) | 2002-05-02 | 2002-05-02 | Biological products |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004501459A Division JP4486494B2 (ja) | 2002-05-02 | 2003-05-02 | 生物学的製剤 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013140245A Division JP5920934B2 (ja) | 2002-05-02 | 2013-07-04 | 生物学的製剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010022372A JP2010022372A (ja) | 2010-02-04 |
JP2010022372A5 true JP2010022372A5 (ja) | 2010-04-22 |
JP5377173B2 JP5377173B2 (ja) | 2013-12-25 |
Family
ID=9935990
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004501459A Expired - Lifetime JP4486494B2 (ja) | 2002-05-02 | 2003-05-02 | 生物学的製剤 |
JP2009205660A Expired - Lifetime JP5377173B2 (ja) | 2002-05-02 | 2009-09-07 | 生物学的製剤 |
JP2013140245A Expired - Lifetime JP5920934B2 (ja) | 2002-05-02 | 2013-07-04 | 生物学的製剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004501459A Expired - Lifetime JP4486494B2 (ja) | 2002-05-02 | 2003-05-02 | 生物学的製剤 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013140245A Expired - Lifetime JP5920934B2 (ja) | 2002-05-02 | 2013-07-04 | 生物学的製剤 |
Country Status (35)
Country | Link |
---|---|
US (8) | US7355011B2 (ja) |
EP (1) | EP1504035B9 (ja) |
JP (3) | JP4486494B2 (ja) |
KR (3) | KR101386376B1 (ja) |
CN (3) | CN101134779B (ja) |
AT (1) | ATE462729T3 (ja) |
AU (1) | AU2003223007C1 (ja) |
BE (1) | BE2017C068I2 (ja) |
CA (1) | CA2484420C (ja) |
CO (1) | CO5631451A2 (ja) |
CY (3) | CY1110134T1 (ja) |
DE (1) | DE60331910D1 (ja) |
DK (1) | DK1504035T6 (ja) |
EC (1) | ECSP045470A (ja) |
ES (1) | ES2341708T7 (ja) |
FR (1) | FR17C1062I2 (ja) |
GB (1) | GB0210121D0 (ja) |
HK (2) | HK1071762A1 (ja) |
HU (2) | HUS1700056I1 (ja) |
IL (1) | IL164923A (ja) |
LT (2) | LTC1504035I2 (ja) |
LU (2) | LUC00057I2 (ja) |
MX (1) | MXPA04010787A (ja) |
NL (1) | NL300920I2 (ja) |
NO (1) | NO336201B3 (ja) |
NZ (1) | NZ536757A (ja) |
PL (1) | PL218433B1 (ja) |
PT (1) | PT1504035E (ja) |
RU (1) | RU2342401C2 (ja) |
SG (1) | SG161744A1 (ja) |
SI (1) | SI1504035T1 (ja) |
TW (1) | TWI324161B (ja) |
UA (1) | UA92580C2 (ja) |
WO (1) | WO2003093320A2 (ja) |
ZA (1) | ZA200408851B (ja) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2461351C (en) * | 2001-09-26 | 2014-08-05 | Ira H. Pastan | Mutated anti-cd22 antibodies with increased affinity to cd22-expressing leukemia cells |
US20110045005A1 (en) | 2001-10-19 | 2011-02-24 | Craig Crowley | Compositions and methods for the treatment of tumor of hematopoietic origin |
WO2003072736A2 (en) | 2002-02-21 | 2003-09-04 | Duke University | Reagents and treatment methods for autoimmune diseases |
GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
EP1507556B1 (en) * | 2002-05-02 | 2016-07-27 | Wyeth Holdings LLC | Calicheamicin derivative-carrier conjugates |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
AR052774A1 (es) * | 2004-10-08 | 2007-04-04 | Wyeth Corp | Inmunoterapia para trastornos autoinmunes |
SG162788A1 (en) | 2005-06-14 | 2010-07-29 | Amgen Inc | Self-buffering protein formulations |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
EP2650306A1 (en) | 2006-03-06 | 2013-10-16 | Aeres Biomedical Limited | Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
JP2009532336A (ja) * | 2006-03-06 | 2009-09-10 | メディミューン,エルエルシー | ヒト化抗cd22抗体、並びに腫瘍、移植及び自己免疫疾患の治療におけるこれらの使用 |
MX2008015132A (es) * | 2006-05-30 | 2008-12-10 | Genentech Inc | Anticuerpos e inmunoconjugados y sus usos. |
JP5398538B2 (ja) | 2006-12-01 | 2014-01-29 | メダレックス・リミテッド・ライアビリティ・カンパニー | Cd22に結合するヒト抗体およびその使用 |
WO2009124109A1 (en) | 2008-04-04 | 2009-10-08 | The Government Of The U.S. A. As Represented By The Secretary Of The Dept. Of Health &Human Services | Human monoclonal antibodies specific for cd22 |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
US9238878B2 (en) * | 2009-02-17 | 2016-01-19 | Redwood Bioscience, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
EP3211094A3 (en) | 2009-09-03 | 2017-11-01 | F. Hoffmann-La Roche AG | Methods for treating, diagnosing, and monitoring rheumatoid arthritis |
CN103415621A (zh) | 2011-01-14 | 2013-11-27 | 雷德伍德生物科技股份有限公司 | 醛标记免疫球蛋白多肽及其使用方法 |
BR112013021725A2 (pt) | 2011-02-28 | 2016-11-01 | Genentech Inc | marcadores biológicos e métodos para prever resposta aos antagonistas de células b |
US9856323B2 (en) * | 2012-04-26 | 2018-01-02 | Bioatla, Llc | Anti-CD22 antibodies |
WO2014008404A1 (en) | 2012-07-03 | 2014-01-09 | Washington University | Antibodies to tau |
US9181343B2 (en) | 2012-07-19 | 2015-11-10 | Redwood Bioscience Inc. | Antibody specific for CD22 and methods of use thereof |
WO2014065961A1 (en) * | 2012-10-24 | 2014-05-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | M971 chimeric antigen receptors |
CN103214578B (zh) * | 2013-05-10 | 2014-05-28 | 北京东方百泰生物科技有限公司 | 一种新型的人源化抗cd22抗体 |
US9381205B2 (en) | 2013-11-04 | 2016-07-05 | Pfizer, Inc. | Anti-EFNA4 antibody-drug conjugates |
GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
TWI734975B (zh) | 2014-06-27 | 2021-08-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
EP4056588A1 (en) * | 2015-04-08 | 2022-09-14 | Novartis AG | Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car)- expressing cell |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
GB201601077D0 (en) * | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
JP2019515677A (ja) | 2016-04-26 | 2019-06-13 | アール.ピー.シェーラー テクノロジーズ エルエルシー | 抗体複合体ならびにそれを作製および使用する方法 |
GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
MX2019004580A (es) | 2016-10-21 | 2019-08-12 | Amgen Inc | Formulaciones farmaceuticas y metodos para prepararlas. |
SG11202009525VA (en) * | 2018-03-30 | 2020-10-29 | Eureka Therapeutics Inc | Constructs targeting cd22 and uses thereof |
AU2021250615A1 (en) * | 2020-04-02 | 2022-12-01 | Nanjing IASO Biotechnology Co., Ltd. | Fully human anti-human CD22 chimeric antigen receptor and application thereof |
WO2022042494A1 (zh) * | 2020-08-27 | 2022-03-03 | 深圳市菲鹏生物治疗股份有限公司 | Cd22抗体及其应用 |
WO2022262783A1 (zh) * | 2021-06-16 | 2022-12-22 | 西安宇繁生物科技有限责任公司 | 抗cd22的全人源抗体或其抗原结合片段及其制备方法和应用 |
IL311090A (en) * | 2021-08-27 | 2024-04-01 | Peptron Inc | A novel ANTI-MUC1 antibody and its use |
WO2024102693A2 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Il-18-fc fusion proteins |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3957362A (en) * | 1972-10-02 | 1976-05-18 | Corneal Sciences, Inc. | Hydrogels and articles made therefrom |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5134075A (en) * | 1989-02-17 | 1992-07-28 | Oncogen Limited Partnership | Monoclonal antibody to novel antigen associated with human tumors |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
CA2064555A1 (en) * | 1990-06-27 | 1991-12-28 | Arnold J. Levine | Probes for detecting mutant p53 |
CZ282603B6 (cs) * | 1991-03-06 | 1997-08-13 | Merck Patent Gesellschaft Mit Beschränkter Haftun G | Humanizované a chimerické monoklonální protilátky |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
US5714340A (en) * | 1992-12-22 | 1998-02-03 | Johnson & Johnson Clinical Diagnostics, Inc. | Immunoassay elements having a receptor zone |
US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
US5436265A (en) * | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
EP0804237B8 (en) * | 1994-01-25 | 2006-11-08 | Elan Pharmaceuticals, Inc. | Humanized antibodies against leukocyte adhesion molecule vla-4 |
JP2002503943A (ja) | 1994-08-12 | 2002-02-05 | ミリアド・ジェネティックス・インコーポレイテッド | 17q−連鎖乳癌および卵巣癌感受性遺伝子におけるイン・ビボ突然変異および多形性 |
ATE306930T1 (de) | 1994-08-12 | 2005-11-15 | Immunomedics Inc | Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper |
US5714586A (en) * | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) * | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
WO1998019704A1 (en) * | 1996-11-01 | 1998-05-14 | Smithkline Beecham Corporation | Human monoclonal antibodies |
US20020141990A1 (en) * | 1996-11-01 | 2002-10-03 | Smithkline Beecham Corporation | Anti-RSV human monoclonal antibodies |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
US7541034B1 (en) | 1997-03-20 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors |
US6183744B1 (en) | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
EP0999853B1 (en) | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
AT408613B (de) * | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
KR100345463B1 (ko) * | 1998-11-19 | 2003-01-08 | 주)녹십자 | B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법 |
EP1194167B1 (en) * | 1999-06-09 | 2009-08-19 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
BR0014734A (pt) * | 1999-10-12 | 2002-06-18 | Connex Ges Zur Optimierung Von | Método melhorado para detectar microorganismos resistentes a ácido na evacuação |
US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
SG136804A1 (en) * | 2000-07-12 | 2007-11-29 | Idec Pharma Corp | Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications |
CN1205479C (zh) * | 2000-10-31 | 2005-06-08 | 杨梦甦 | 免疫学诊断蛋白芯片制备方法 |
GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
EP1507556B1 (en) | 2002-05-02 | 2016-07-27 | Wyeth Holdings LLC | Calicheamicin derivative-carrier conjugates |
EP2650306A1 (en) * | 2006-03-06 | 2013-10-16 | Aeres Biomedical Limited | Humanized Anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
-
2002
- 2002-05-02 GB GBGB0210121.0A patent/GB0210121D0/en not_active Ceased
-
2003
- 2003-05-02 KR KR1020127025129A patent/KR101386376B1/ko active IP Right Grant
- 2003-05-02 US US10/428,408 patent/US7355011B2/en active Active
- 2003-05-02 SG SG200608406-5A patent/SG161744A1/en unknown
- 2003-05-02 CA CA2484420A patent/CA2484420C/en not_active Expired - Lifetime
- 2003-05-02 CN CN2007100852904A patent/CN101134779B/zh not_active Expired - Lifetime
- 2003-05-02 WO PCT/GB2003/001934 patent/WO2003093320A2/en active Application Filing
- 2003-05-02 ES ES03718974.3T patent/ES2341708T7/es active Active
- 2003-05-02 PL PL373277A patent/PL218433B1/pl unknown
- 2003-05-02 PT PT03718974T patent/PT1504035E/pt unknown
- 2003-05-02 KR KR1020047017615A patent/KR101156796B1/ko active IP Right Grant
- 2003-05-02 RU RU2004135103/13A patent/RU2342401C2/ru active
- 2003-05-02 MX MXPA04010787A patent/MXPA04010787A/es active IP Right Grant
- 2003-05-02 DE DE60331910T patent/DE60331910D1/de not_active Expired - Lifetime
- 2003-05-02 SI SI200331804T patent/SI1504035T1/sl unknown
- 2003-05-02 UA UA20041209866A patent/UA92580C2/ru unknown
- 2003-05-02 CN CNB038150433A patent/CN100384878C/zh not_active Expired - Lifetime
- 2003-05-02 KR KR1020107027192A patent/KR101238970B1/ko active IP Right Grant
- 2003-05-02 DK DK03718974.3T patent/DK1504035T6/en active
- 2003-05-02 AU AU2003223007A patent/AU2003223007C1/en active Active
- 2003-05-02 NZ NZ536757A patent/NZ536757A/en not_active IP Right Cessation
- 2003-05-02 CN CN201310021287.1A patent/CN103172742B/zh not_active Expired - Lifetime
- 2003-05-02 AT AT03718974T patent/ATE462729T3/de unknown
- 2003-05-02 JP JP2004501459A patent/JP4486494B2/ja not_active Expired - Lifetime
- 2003-05-02 EP EP03718974.3A patent/EP1504035B9/en not_active Expired - Lifetime
- 2003-05-02 TW TW092112182A patent/TWI324161B/zh not_active IP Right Cessation
-
2004
- 2004-10-28 IL IL164923A patent/IL164923A/en active IP Right Grant
- 2004-11-02 ZA ZA2004/08851A patent/ZA200408851B/en unknown
- 2004-11-02 NO NO20044742A patent/NO336201B3/no not_active IP Right Cessation
- 2004-11-30 CO CO04120665A patent/CO5631451A2/es active IP Right Grant
- 2004-12-02 EC EC2004005470A patent/ECSP045470A/es unknown
-
2005
- 2005-05-27 HK HK05104462.6A patent/HK1071762A1/xx not_active IP Right Cessation
-
2006
- 2006-09-11 US US11/519,585 patent/US20070059307A1/en not_active Abandoned
-
2008
- 2008-09-23 US US12/235,724 patent/US7919606B2/en not_active Expired - Lifetime
-
2009
- 2009-09-07 JP JP2009205660A patent/JP5377173B2/ja not_active Expired - Lifetime
-
2010
- 2010-06-03 CY CY20101100492T patent/CY1110134T1/el unknown
-
2011
- 2011-03-16 US US13/049,087 patent/US8895714B2/en active Active
-
2012
- 2012-07-13 US US13/548,542 patent/US20120302739A1/en not_active Abandoned
-
2013
- 2013-07-04 JP JP2013140245A patent/JP5920934B2/ja not_active Expired - Lifetime
- 2013-12-12 HK HK13113804.4A patent/HK1186479A1/zh not_active IP Right Cessation
-
2016
- 2016-03-14 US US15/069,078 patent/US20160326247A1/en not_active Abandoned
-
2017
- 2017-01-27 US US15/417,973 patent/US20170145114A1/en not_active Abandoned
- 2017-12-20 CY CY2017046C patent/CY2017046I2/el unknown
- 2017-12-21 FR FR17C1062C patent/FR17C1062I2/fr active Active
- 2017-12-21 LT LTPA2017044C patent/LTC1504035I2/lt unknown
- 2017-12-21 LU LU00057C patent/LUC00057I2/en unknown
- 2017-12-21 CY CY2017045C patent/CY2017045I2/el unknown
- 2017-12-21 BE BE2017C068C patent/BE2017C068I2/nl unknown
- 2017-12-21 LT LTPA2017043C patent/LTPA2017043I1/lt unknown
- 2017-12-21 LU LU00058C patent/LUC00058I2/en unknown
- 2017-12-21 NL NL300920C patent/NL300920I2/nl unknown
- 2017-12-22 HU HUS1700056C patent/HUS1700056I1/hu unknown
- 2017-12-22 HU HUS1700055C patent/HUS1700055I1/hu unknown
-
2021
- 2021-01-19 US US17/151,911 patent/US20210371547A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010022372A5 (ja) | ||
JP2016512551A5 (ja) | ||
NZ596136A (en) | Anti-cd100 antibodies and methods for using the same | |
HRP20190932T1 (hr) | Molekule protutijela koje se vežu na il-17a i il-17f | |
HRP20191983T1 (hr) | Konstrukti protutijela za cdh19 i cd3 | |
JP2006506955A5 (ja) | ||
JP2016511750A5 (ja) | ||
JP2017534256A5 (ja) | ||
HRP20201747T1 (hr) | Bispecifične antigen vezujuće molekule koje aktiviraju t stanice, protiv folr1 i cd3 | |
HRP20191697T1 (hr) | Vezujuće molekule za bcma i cd3 | |
JP2017505604A5 (ja) | ||
JP2014534242A5 (ja) | ||
JP2015504306A5 (ja) | ||
JP2015509948A5 (ja) | ||
RU2004135103A (ru) | Антитела, специфичные к cd22 человека, и их применения в терапии и диагностике | |
AR080243A1 (es) | Composiciones y metodos para el diagnostico y tratamiento de tumores | |
NZ603045A (en) | Tnf-alpha binding proteins | |
RU2451689C2 (ru) | Новые антипролиферативные антитела | |
JP2017522892A5 (ja) | ||
NZ596712A (en) | Anti cxcr4 antibodies for the treatment of hiv | |
RU2008149918A (ru) | Антитела к nkg2a и их применения | |
JP2013524773A5 (ja) | ||
JP2016536020A5 (ja) | ||
PE20211863A1 (es) | Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap | |
RU2010133892A (ru) | Гуманизированные моноклональные антитела против человеческого nkg2a |